AHA: Lowering TGs With Pemafibrate Does Not Cut CV Risk in T2DM
In patients with T2DM, hypertriglyceridemia, and low HDL cholesterol levels, the risk for cardiovascular events was not lower with pemafibrate versus placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.